Jupiter Asset Management Ltd. Has $31.48 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Jupiter Asset Management Ltd. lessened its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 51.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 78,166 shares of the pharmaceutical company's stock after selling 81,761 shares during the quarter. Jupiter Asset Management Ltd.'s holdings in Vertex Pharmaceuticals were worth $31,477,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in VRTX. State Street Corp lifted its holdings in shares of Vertex Pharmaceuticals by 0.8% in the third quarter. State Street Corp now owns 11,816,249 shares of the pharmaceutical company's stock valued at $5,495,501,000 after buying an additional 90,173 shares during the period. Jennison Associates LLC lifted its holdings in Vertex Pharmaceuticals by 18.1% in the 3rd quarter. Jennison Associates LLC now owns 5,550,386 shares of the pharmaceutical company's stock valued at $2,581,373,000 after acquiring an additional 851,054 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Vertex Pharmaceuticals by 17.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company's stock valued at $2,231,858,000 after purchasing an additional 704,421 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Vertex Pharmaceuticals by 5.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,905,705 shares of the pharmaceutical company's stock worth $1,351,385,000 after purchasing an additional 159,693 shares during the last quarter. Finally, Janus Henderson Group PLC raised its holdings in shares of Vertex Pharmaceuticals by 4.1% in the 3rd quarter. Janus Henderson Group PLC now owns 2,516,831 shares of the pharmaceutical company's stock worth $1,170,506,000 after purchasing an additional 100,114 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Activity at Vertex Pharmaceuticals

In related news, EVP David Altshuler sold 3,231 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the sale, the executive vice president now owns 26,512 shares of the company's stock, valued at $13,256,000. This trade represents a 10.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Ourania Tatsis sold 244 shares of the business's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total value of $111,034.64. Following the sale, the executive vice president now owns 67,695 shares of the company's stock, valued at approximately $30,805,286.70. The trade was a 0.36 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,315 shares of company stock valued at $2,121,012 in the last three months. Corporate insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Price Performance

NASDAQ:VRTX traded up $7.50 during trading hours on Thursday, reaching $502.92. The company had a trading volume of 1,699,021 shares, compared to its average volume of 1,491,696. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. The stock has a 50-day moving average of $455.79 and a two-hundred day moving average of $461.87. The firm has a market capitalization of $129.14 billion, a PE ratio of -228.60, a PEG ratio of 2.11 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. Analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on VRTX. Wells Fargo & Company lowered Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 price objective for the company. in a research note on Thursday, January 30th. Citigroup started coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, November 14th. They issued a "buy" rating and a $575.00 price target for the company. William Blair reiterated an "outperform" rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. HC Wainwright restated a "buy" rating and issued a $550.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Finally, Barclays raised their target price on Vertex Pharmaceuticals from $435.00 to $467.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 11th. Ten investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $506.70.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.